Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Dieci, M.V. ; Prat, A. ; Tagliafico, E. ; Paré, L. ; Ficarra, G. ; Bisagni, G. ; Piacentini, F. ; Generali, D.G. ; Conte, P. ; Guarneri, V.

Annals of oncology, 2016-10, Vol.27 (10), p.1867-1873 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível